Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Key Projections for the CAGR of the Convalescent Plasma Therapy Market Size From 2025 to 2034?

In recent times, the market size of convalescent plasma therapy has experienced significant expansion. The market will undergo a growth from a value of $0.05 billion in 2024 to $0.06 billion in 2025, reflecting a compound annual growth rate (CAGR) of 11.1%. Factors contributing to the growth during the historic period include pandemics and epidemics of infectious diseases, advancements in immunotherapy research, the implementation of emergency use authorization (eua), the availability of patients, as well as the heightened awareness of clinicians and the general public.

In the coming years, a swift expansion is expected in the market size of convalescent plasma therapy. It is anticipated to increase to $0.09 billion by 2029, accelerating at a compound annual growth rate (CAGR) of 13.6%. The upcoming growth can be credited to factors like mutating pathogens, advancements in immunotherapies, regulatory structures, global readiness and public health endeavours. Key trends that will characterize this forecast period encompass standardized gathering and processing, specific plasma components, bespoke treatments, telemedicine and remote patient monitoring, as well as exploration into long-term impacts.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3233&type=smp

What External and Internal Drivers Are Contributing to the Growth of theConvalescent Plasma Therapy Market?

The rise in the therapeutic efficacy and safety observed during the clinical trials for CPT on COVID-19 patients could serve as a catalyst for the market expansion in the predicted timeline. Convalescent plasma transfusion has historically gained attention for combating detrimental infectious disease outbreaks such as SARS-1, Middle East Respiratory Syndrome (MERS), and 2009 H1N1. A study conducted by the Houston Methodist hospital in June 2022, aiming to appraise the safety and efficacy of COVID-19 convalescent plasma therapy, concluded the therapy to be safe with zero reported adverse events and efficient with a recovery rate of 76%. A research published in the Journal of Medical Virology in May 2020 indicated that convalescent plasma therapy could lower the mortality rate in severely ill patients, provide advantage to clinical symptoms, and result in the rise of neutralizing antibody titers and the disappearance of SARS-CoV-2 RNA. The recognized safety and efficacy of convalescent plasma therapy in treating COVID-19 patients are anticipated to accelerate the growth of the global convalescent plasma therapy market.

What Segment Types Define the Convalescent Plasma Therapy Market Structure?

The convalescent plasma therapymarket covered in this report is segmented –

1) By Antibody type: IgM; IgG; IgA

2) By Application: Prophylaxis; Treatment

3) By End-Users: Hospitals And Clinics; Laboratories And Research institutes

Subsegments:

1) By IgM: Early-Stage Infection Plasma; Acute Phase Plasma; Other IgM-Based Plasma Products

2) By IgG: High Titer IgG Plasma; Standard IgG Plasma; Other IgG-Based Plasma Products

3) By IgA: Plasma Rich In IgA; Specific IgA Antibody Plasma; Other IgA-Based Plasma Products

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=3233&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Convalescent Plasma Therapy Market?

North America was the largest region in the convalescent plasma therapy market in 2024. Western Europe was the second largest region in the convalescent plasma therapy market. The regions covered in the convalescent plasma therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Long-Term Trends Are Transforming the Competitive Landscape of the Convalescent Plasma Therapy Market?

Potential therapeutic treatments for COVID-19, like antibody-based immunotherapy, are offering new opportunities for the convalescent plasma therapy market. This therapy uses antibodies created to combat the coronavirus in a donor, enhancing the immune response of the recipient. Companies are beginning trials, forging collaborations and investing in antibody-based treatments for the virus. In August 2023, American biotechnology company, Regeneron Pharmaceuticals Inc., joined forces with the Biomedical Advanced Research and Development Authority (BARDA), in an effort to assist with the clinical development, manufacturing, and regulatory licensing processes for a future-generation monoclonal antibody therapy for COVID-19, aimed at preventing SARS-CoV-2 infection. This alliance forms part of Project NextGen, a U.S. Department of Health and Human Services (HHS) initiative to build a range of updated COVID-19 vaccines and treatments. Compliant with the project, Regeneron will independently create and propose an antibody candidate, then BARDA and Regeneron will evaluate and choose it for further research, manufacturing, and regulatory undertakings. The growing emphasis on antibody-based treatments for COVID-19 suggests a bright future for the convalescent plasma therapy market.

View the full report here:

https://www.thebusinessresearchcompany.com/report/convalescent-plasma-therapy-global-market-report

What Is the Definition of the Convalescent Plasma Therapy Market?

Convalescent plasma is plasma that has been collected from people who have recovered or are convalescing and contains antibodies against the infection-causing microorganism. It is used for the treatment of patients infected by the respective pathogen.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3233

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model